阅读说明：本技术 使用多能干细胞的免疫细胞的分化 (Differentiation of immune cells using pluripotent stem cells ) 是由 金定炫 韩孝媛 徐乡姬 韩炯俊 于 2018-10-12 设计创作，主要内容包括：本发明涉及通过使用多能干细胞来诱导造血干细胞或巨噬细胞的分化的方法、以及用于诱导分化的组合物。具体地,涉及在多能干细胞中包含骨形态发生蛋白4的用于诱导分化造血干细胞的组合物、或包含骨形态发生蛋白4及巨噬细胞集落刺激因子的用于诱导分化巨噬细胞的组合物、使用它们诱导分化的方法。本发明的优点在于,由于诱导分化的方法中使用的细胞因子的种类少,分化方法简单,因此与现有诱导分化的方法相比,分化效率提高了数十倍且分化的细胞的收率高。(The present invention relates to a method for inducing differentiation of hematopoietic stem cells or macrophages by using pluripotent stem cells, and a composition for inducing differentiation. Specifically, the present invention relates to a composition for inducing differentiation of hematopoietic stem cells, which comprises bone morphogenetic protein 4 in pluripotent stem cells, or a composition for inducing differentiation of macrophages, which comprises bone morphogenetic protein 4 and a macrophage colony stimulating factor, and a method for inducing differentiation using the same. The present invention has the advantages that the differentiation efficiency is improved by tens of times and the yield of differentiated cells is high compared to the existing differentiation induction method because the types of cytokines used in the differentiation induction method are few and the differentiation method is simple.)

1. A method of inducing differentiation of hematopoietic stem cells, comprising:

step 1), culturing pluripotent stem cells in a medium for inducing differentiation of hematopoietic stem cells, the medium comprising bone morphogenetic protein 4;

step 2), culturing the pluripotent stem cells by treating vascular endothelial growth factors and stem cell factors; and

step 3), treating the pluripotent stem cells with thrombopoietin, interleukin-6, interleukin-3 and FMS-like tyrosine kinase 3.

2. The method for inducing differentiation of hematopoietic stem cells according to claim 1, wherein in the step 1), CDDO methyl ester is further treated.

3. The method for inducing differentiation of hematopoietic stem cells according to claim 1, wherein one or more of activin A, basic fibroblast growth factor and transforming growth factor b are not additionally included in step 1).

4. The method for inducing differentiation of hematopoietic stem cells according to claim 1, wherein in step 1), bone morphogenetic protein 4 is contained at a concentration of 20-100 ng/ml.

5. The method for inducing differentiation of hematopoietic stem cells according to claim 1, wherein in step 1), the bone morphogenetic protein 4 is treated at a low concentration and then treated at a high concentration.

6. The method for inducing differentiation of hematopoietic stem cells according to claim 1, wherein in step 1), the medium for inducing differentiation of hematopoietic stem cells is albumin, a polyvinyl alcohol essential lipid.

7. A method of inducing macrophage differentiation comprising:

step 1), culturing pluripotent stem cells in a medium for inducing differentiation of hematopoietic stem cells, the medium comprising bone morphogenetic protein 4;

step 2), culturing the pluripotent stem cells by treating vascular endothelial growth factors and stem cell factors;

step 3) inducing hematopoietic stem cell differentiation by treating said pluripotent stem cells with thrombopoietin, interleukin-6, interleukin-3, and FMS-like tyrosine kinase 3; and

step 4) adding the differentiated hematopoietic stem cells to a macrophage differentiation-inducing medium containing a macrophage colony-stimulating factor for culture.

8. The method for inducing macrophage differentiation according to claim 7, wherein in said step 4), when the macrophages are cultured, the cell density is maintained at 1 x 10⁵Cells/cm²The above.

9. A hematopoietic stem cell characterized by inducing differentiation from a pluripotent stem cell according to the method for inducing differentiation of a hematopoietic stem cell of claim 1.

10. A macrophage cell, wherein the differentiation is induced from the pluripotent stem cell according to the method for inducing macrophage differentiation of claim 7.

11. A composition for inducing differentiation of hematopoietic stem cells derived from pluripotent stem cells, comprising at least one member selected from the group consisting of bone morphogenetic protein 4, vascular endothelial growth factor, stem cell factor, thrombopoietin, interleukin-6, interleukin-3, CDDO methyl ester and FMS-like tyrosine kinase 3.

12. A composition for inducing differentiation of macrophages derived from pluripotent stem cells, comprising at least one member selected from the group consisting of bone morphogenetic protein 4, vascular endothelial growth factor, stem cell factor, thrombopoietin, interleukin-6, interleukin-3, FMS-like tyrosine kinase 3, and macrophage colony stimulating factor.

Technical Field

The present invention relates to a method for inducing differentiation of hematopoietic stem cells or macrophages from pluripotent stem cells and a composition for inducing differentiation thereof. The differentiated hematopoietic stem cells can also be differentiated into bone marrow (myeloid) type cells such as macrophages, neutrophils, monocytes and the like.

The method for inducing differentiation of the present invention is characterized in that, in the step of differentiating macrophages from pluripotent stem cells, embryoid bodies (cell aggregates) are not formed but directly differentiated. Also, the method of using an additive for inducing differentiation in a stepwise manner, a method of excluding a composition for inhibiting differentiation, a method of using albumin-polyvinyl alcohol-essential lipid (APEL) as a minimal medium for differentiation, and the like have an excellent yield as compared with the known methods.

Background

Pluripotent stem cells refer to stem cells in an undifferentiated state that are capable of differentiating into all cells of the human body. Research in the field of stem cells, formally started after human embryonic stem cells (hESCs) were established in the late 1990 s, has taken a breakthrough from the mid-2000 s to the preparation of Induced Pluripotent Stem Cells (iPSCs), leading to a dramatic development. Further research in the stem cell field has been actively conducted recently with respect to the success in establishing human somatic cell nuclear transfer ESCs (hSCNT-ESCs).

In such research fields using stem cells, research is being conducted on methods of differentiating cells into desired species in cell culture, and particularly, research on schemes of differentiating them more efficiently is being conducted as a major problem. Stem cells in an undifferentiated state lose the characteristics of stem cells as they differentiate and gradually have the characteristics inherent to differentiated cells, and in this process, various signal substances such as morphogen (morphogen) and growth factor (growth factor) are sequentially and in combination according to the generation procedure. Differentiation was induced by adding these factors to the stem cell culture fluid in culture.

The innate immune response is the first line of defense in protecting our body from external invading pathogens, also known as nonspecific immunity. Neutrophils, monocytes, macrophages, etc. are involved in the innate immune response, which begins independent of the type of pathogen or the presence or absence of an infectious history.

Macrophages, which are the cells responsible for the innate immune response, are distributed throughout the body. Most macrophages are sticky and contain dust cells, microglia, cooper cells, langerhans cells, etc., which when they recognize an antigen phagocytose the antigen or secrete toxins to destroy the antigen, triggering an immune response by delivering the antigen to lymphocytes. Macrophages exist in some blood as undifferentiated monocytes (monocytes), which can differentiate into dendritic cells or macrophages as desired, and the various signaling substances are involved in the differentiation of macrophages.

As such, desired cells can be obtained by inducing differentiation of pluripotent stem cells, and in particular, differentiation into immune cells as in the present invention can be used for various disease diagnosis or drug screening methods. Thus, there is a need to develop a novel method for inducing stem cell differentiation and a composition for inducing differentiation that can improve differentiation efficiency and the yield of final cells.

Therefore, the present inventors have confirmed a method of successfully inducing differentiation from pluripotent stem cells into macrophages via hematopoietic stem cells by subjecting various minimal media to tests, changes in cytokine composition, order regulation of signaling substances, and the like, in order to develop a method of inducing differentiation of hematopoietic stem cells or macrophages with high efficiency by improving the previously developed protocols, and have completed the present invention.

It was confirmed that macrophages produced by the novel method for inducing differentiation of the present invention have very high similarity to macrophages present in humans and thus can be utilized in various ways.

Prior patent literature

Non-patent document

Meguma K.Saito et al, Plos One, Published: April 3, 2013(https:// doi.org/10.1371/journal.bone.0059243)

Patent document

Korean laid-open patent No. 10-2011-

International publication patent No. 2016114723

U.S. patent No. 8372642

Disclosure of Invention

Technical problem

The present invention aims to provide a method for efficiently inducing differentiation of bone marrow (myeloid) hematopoietic stem cells and macrophages from pluripotent stem cells by regulating various signaling substances including bone morphogenetic protein 4(BMP4), macrophage colony stimulating factor (M-CSF), and the like.

It is another object of the present invention to provide a composition for inducing differentiation of bone marrow hematopoietic stem cells and macrophages derived from pluripotent stem cells, the composition comprising bone morphogenetic protein 4(BMP4) and macrophage colony stimulating factor (M-CSF) for performing the method.

Means for solving the problems

In order to solve the problems, the present invention provides a method comprising: a step of maintaining pluripotent stem cells cultured in mTeSR1 or mTeSR8 minimal medium in a dish coated with vitronectin (vitronectin) or matrigel (matrigel); culturing the cells transferred to a medium for inducing differentiation of hematopoietic stem cells, which contains bone morphogenetic protein 4; treating a signal substance to induce differentiation of bone marrow hematopoietic stem cells after treating and culturing vascular endothelial growth factor and stem cell factor; and transferring macrophage colony stimulating factor containing the differentiated hematopoietic stem cells to a macrophage differentiation-inducing medium at 10⁵Cells/cm²The method for inducing differentiation of pluripotent stem cell-derived macrophages according to the above-described density culture step.

In another embodiment, the present invention provides a composition for inducing differentiation of pluripotent stem cell-derived macrophages, comprising an albumin-based polyvinyl alcohol essential lipid (APEL) medium comprising bone morphogenetic protein 4 and macrophage colony stimulating factor.

Specifically, the present invention provides a method for differentiating into hematopoietic stem cells by treating pluripotent stem cells with a high concentration of bone morphogenetic Protein 4(BMP4) for 2 days and a low concentration of bone morphogenetic Protein (VEGF) for 2 days to induce mesoderm (mesoderm) and then treating only cytokines such as Vascular Endothelial Growth Factor (VEGF) and Stem Cell Factor (SCF). In this case, it is characterized in that basic fibroblast growth factor or the like that interferes with differentiation is excluded. Further, the yield of bone marrow hematopoietic progenitor cells is further improved by adding CDDO methyl ester (CDDO methyl ester).

The present invention relates to a method for obtaining only pure bone marrow hematopoietic progenitor cells by treating cytokines such as interleukin 3, interleukin 6, FMS-like tyrosine kinase 3(FLT3) and Thrombopoietin (TPO) in order to mature differentiated hematopoietic stem cells into bone marrow hematopoietic progenitor cells. The procedure is characterized in that it is considered as an effective differentiation method in that the yield of pure myeloid hematopoietic progenitor cells can be increased compared to the existing methods without treating macrophage colony stimulating factor (M-CSF).

The present invention relates to a method for inducing differentiation, which comprises the step of treating only a Macrophage Colony Stimulating Factor (M-CSF) to hematopoietic progenitor cells of bone marrow type to induce differentiation of macrophages.

The method for inducing differentiation of the present invention has the following characteristics: the differentiation efficiency is high, the differentiation is direct without a step of embryoid body formation, so the differentiation method is simple, and the yield of differentiated cells is more than tens of times higher than that of the existing method.

Macrophages differentiated according to the method of inducing differentiation of the present invention are widely used in various fields requiring a large number of cells.

ADVANTAGEOUS EFFECTS OF INVENTION

The method for inducing macrophage differentiation of the present invention includes a step of inducing differentiation from pluripotent stem cells into bone marrow (myoid) -like hematopoietic stem cells and then inducing differentiation into macrophages, and has the effects of simple differentiation steps, a small number of cytokines, and a high yield of differentiated cells due to an increase in differentiation efficiency, as the method for inducing differentiation by using various signal substances including bone morphogenetic protein 4, macrophage colony stimulating factor, and the like, and a composition for inducing differentiation including the signal substances.

Drawings

FIG. 1 is a diagram specifically illustrating the method for inducing differentiation of hematopoietic stem cells of myeloid type according to the present invention, which is a hematopoietic stem cell differentiation protocol showing four minimal media for hematopoietic stem cell differentiation.

Fig. 2 shows CD34+ CD45+ labeled with fluorescence as a marker specifically expressed only in hematopoietic stem cells for confirming hematopoietic stem cell differentiation results according to respective minimal media.

FIG. 3 shows the yield of CD34+ CD45+ hematopoietic stem cells (HSPC) differentiated by marker expression using a quantitative cell number marker, meaning the number of CD34+ CD45+ hematopoietic stem cells generated from 5 colonies (colony).

Fig. 4 shows a comparison of the yields of CD34+ CD45+ hematopoietic stem cells in the case of treated compound CDDO methyl ester and in the case of no treatment when hematopoietic stem cells were induced to differentiate.

FIG. 5 shows the blood cell differentiation ability of hematopoietic stem cells produced according to the minimal medium of the present invention as colony forming ability. Macrophage colony-forming unit (GM) shows the ability of myeloid blood cells containing macrophages to differentiate. The hematopoietic stem cell differentiation method of the present invention based on the albumin-polyvinyl alcohol essential lipid (APEL) minimal medium often has the ability to differentiate into myeloid cells.

FIG. 6 is a diagram specifically illustrating the method of inducing macrophage differentiation of the present invention, showing the entire scheme of inducing differentiation.

Fig. 7 is a schematic diagram comparing with the known scheme. In contrast to the known protocol, basic fibroblast growth factor was removed in step 2, stem cell factor and macrophage colony stimulating factor were removed in step 3 and IL6 was added. FL3 and granulocyte macrophage stimulating factor were removed in step 4. The yield of macrophages was increased by about 3.8-fold compared to the known protocol on day 28 basis and by 100-fold compared to the amount produced up to the end. This indicates that the present invention is a method of reducing the amount of cytokines while increasing the yield.

FIG. 8 shows the production efficiency of macrophages in the present invention, showing macrophage-specific marker expression when floating hematopoietic stem cells differentiate into macrophages using fluorescent labeling.

Fig. 9 shows the percentage (%) of cells expressing macrophage specific marker, i.e., quantitatively shows purity.

FIG. 10 quantitatively shows the number of macrophages produced from 20 colonies of pluripotent stem cells.

Fig. 11 shows a graph in which the percentage of cells that fluoresce was analyzed and quantified by a flow cytometer as a result of confirming the macrophage phagocytosis of the cells by opsonized microbeads, in order to confirm that differentiated macrophages are completed.

Fig. 12 shows the results of analyzing the similarity of differentiated macrophages and human macrophages by gene expression pattern, which shows the results of statistically confirming the relative likelihoods of the gene expression of the differentiated macrophages (imacs) of the present invention, human monocyte-derived macrophages (hMDM) isolated from human blood, and human macrophage cell line (Thp-1) by Principal Component Analysis (PCA).

FIG. 13 is a graph showing the probability of infection associated with viruses and bacteria of differentiated macrophages, in which differentiated macrophages were infected with H3N2 cold virus or phagocytophilic anaplasma, and then macrophages were stained by a centrifugal smear (cytospin) method and observed with a microscope.

Fig. 14 is a graph showing the results of observing intracellular infected viruses and bacteria of the infected macrophages with a Transmission Electron Microscope (TEM).

Fig. 15 is a graph showing an increase in Reactive Oxygen Species (ROS) after infection of virus or bacteria into differentiated macrophages.

Fig. 16 is a graph showing that the secretion of inflammatory cytokines increases after infection of viruses or bacteria to differentiated macrophages.

Fig. 17 is a result of demonstrating infection possibility of tubercle bacillus to differentiated macrophage, showing infection rate when tubercle bacillus (Mycoplasma Tuberculosis) was treated with multiple infection (MOI) of 0 to 20 after infection, showing infection rate as amount of macrophage to tubercle bacillus.

Detailed Description

The present inventors have studied a method for classifying pluripotent stem cells into hematopoietic stem cells or macrophages, and have completed the method of the present invention, which uses a small amount of cytokines and has high differentiation efficiency and high macrophage yield.

Specifically, the method for inducing macrophage differentiation of the present invention comprises: a step of culturing pluripotent stem cells in mTeSR1 or mTeSR8 minimal medium and maintaining the cells in an undifferentiated state in a dish coated with matrigel (matrigel) or vitronectin (vitronectin); a step of maintaining the pluripotent stem cells cultured in the minimal medium at 5 colonies or less per 35 cake dishes; a step of treating only bone morphogenetic protein 4(BMP4) at a high concentration for 2 days and at a low concentration for 2 days based on an albumin-polyvinyl alcohol essential lipid (APEL) medium, and transferring to a hematopoietic stem cell differentiation induction medium for culture; a step of treating the pluripotent stem cells with Vascular Endothelial Growth Factor (VEGF) and Stem Cell Factor (SCF) based on an albumin-polyvinyl alcohol-essential lipid (APEL) medium, culturing the cells, and then treating another signal substance to induce differentiation into hematopoietic stem cells; and transferring the differentiated hematopoietic stem cells to a macrophage differentiation-inducing medium containing macrophage colony-stimulating factor (M-CSF) based on a serum-free cell cryopreservation medium (RPMI) and at 10%⁵Cells/cm²Culturing at the above density.

Bone Morphogenetic Protein (BMP) "is a peptide Growth Factor belonging to the superfamily of Transforming Growth factors (Transforming Growth Factor β - β). Bone Morphogenetic Protein is known to promote differentiation of hepatocytes into osteocytes or chondrocytes in mammals (see: J warming Zhang, Linking Li. BMignaling and stem cell differentiation (2005) Developmental Biology 2841-11). osteoinductive Bone Morphogenetic Protein is used as the first signal molecule during Bone formation when hepatocytes differentiate into osteoblasts, particularly during fracture healing, Bone Morphogenetic Protein 2, Bone Morphogenetic Protein 4, Bone Morphogenetic Protein 7 mainly play a role when Bone is formed (see: M.Eholin, C.A.Living, K.Critical SD, Bone Morphogenetic Protein 2, Bone Morphogenetic Protein 4, Bone Morphogenetic Protein 7) and Bone Morphogenetic Protein (see: Bone Morphogenetic Protein, Bone Morphogenetic Protein 2, Bone Morphogenetic Protein 4, Bone Morphogenetic Protein 7, Bone Morphogenetic Protein 2, Bone Morphogenetic Protein 5, Bone Morphogenetic Protein, Bone Morphogenetic.

The present invention includes the step of culturing in a medium containing bone morphogenetic protein 4, which is one of said bone morphogenetic proteins, to rapidly differentiate pluripotent stem cells or retrodifferentiated stem cells cultured in an undifferentiated state into mesodermal cells.

The bone morphogenetic protein 4 is a protein involved in the signal transduction pathway for inducing pluripotent stem cells to mesoderm, and in the present invention, the method comprises the step of inducing differentiation of pluripotent stem cells cultured in a minimal medium into hematopoietic stem cells as mesoderm cells by culturing the cells by transferring the cells to a differentiation-inducing medium containing the bone morphogenetic protein 4.

Differentiation with an induction medium containing only bone morphogenetic protein 4 is more efficient than the method in which differentiation is carried out with a culture comprising activin a (activin a), basic fibroblast growth factor (bFGF) or transforming growth factor b in known methods. This is expected because cytokines such as basic fibroblast growth factor also serve as undifferentiated retention factors.

The bone morphogenetic protein 4 can be treated at a concentration of 20-100 ng/ml, but is not limited thereto. When the medium is treated at a concentration of 20ng/ml or less, differentiation into mesoderm cannot be induced satisfactorily, and when the medium is treated at a concentration of 100ng/ml or more for a long period of time, there is a problem of low economic efficiency.

Also, the present invention may include a method of culturing bone morphogenetic protein 4(BMP4) for 2 days after treating it for the first time at a concentration of 100ng/ml, and treating it for another 2 days at a concentration of 20 ng/ml. In the present invention, preferably, the bone morphogenetic protein 4 is treated for 4 days and cultured.

The present invention may include a method of further processing and culturing the CDDO methyl ester compound in the bone morphogenetic protein 4 processing step. When the CDDO methyl ester compound is further processed, the productivity of hematopoietic stem cells can be increased by 3 times or more.

The present invention will comprise the step of treating various additional signal substances to differentiate pluripotent stem cells induced to mesoderm on a differentiation induction medium into bone marrow-type hematopoietic stem cells.

The signal substance which can be used in the present invention may include Vascular Endothelial Growth Factor (VEGF), Stem Cell Factor (SCF), Thrombopoietin (TPO), interleukin-6 (interleukin-6, IL-6), interleukin-3 (interleukin-3, IL-3), and FMS-like tyrosine kinase 3(FMS-like tyrosine kinase 3, Flt 3).

The signal substances of the invention may in turn be contained in the induction medium.

When the signal substances for inducing differentiation are treated at the same time, sufficient differentiation cannot be achieved, and when the bone morphogenetic protein 4 is treated first and then the other signal substances are treated in sequence, differentiation can be induced more efficiently. This is because the process of inducing pluripotent stem cells into mesoderm by bone morphogenetic protein 4(BMP4) has an important influence on the whole differentiation induction process.

In one embodiment of the present invention, the method comprises treating vascular endothelial growth factor and stem cell factor and culturing for 2 days, then further treating thrombopoietin, IL6, IL3 and FMS-like tyrosine kinase 3(Flt3) and culturing for more than 10 days, and differentiating into bone marrow hematopoietic stem cells. The step is a step of further processing a signal substance required for differentiation of hematopoietic stem cells, vascular endothelial growth factor and stem cell factor play a role of promoting early differentiation (hemangio blast), and thrombopoietin, IL6, IL3 and FMS-like tyrosine kinase 3, which are sequentially processed, not only contribute to differentiation, but also contribute to the role required for autologous proliferation of hematopoietic stem cells.

The method of post-treating thrombopoietin, IL6, IL3 and FMS-like tyrosine kinase 3 after treating vascular endothelial growth factor and stem cell factor for 2 days first is more effective for differentiation of hematopoietic stem cells than the method of treating vascular endothelial growth factor, stem cell factor, thrombopoietin, IL3, IL 6and FMS-like tyrosine kinase 3 at the same time.

The signal substance is an essential substance in the differentiation of hematopoietic stem cells, and preferably, is sequentially treated to undergo a process of differentiating into mesodermal cells and then differentiating into hematopoietic stem cells.

The hematopoietic stem cells of the present invention have a characteristic as Granulocyte-Macrophage progenitors (GMP), which are intermediate steps for differentiation into macrophages (macrophages), megakaryocytes (megakaryocytes) or neutrophils (neutrophiles). The induction of such differentiation is influenced by the kind of the signal substance and the treatment sequence. In the case of differentiation induced by the conditions, granulocyte-macrophage progenitor cells are produced most.

The minimal medium used in the present invention may be Albumin polyvinyl alcohol Essential Lipids (APEL), which are animal serum free (serum) media that do not contain animal derived components, a medium first developed by Andrew g. The albumin polyvinyl alcohol essential lipid comprises the composition of table 1 below.

Albumin polyvinyl alcohol essential lipid mediator (APEL media) composition

Also, the present invention includes a step of differentiating macrophages from the differentiated hematopoietic stem cells. In the present invention, macrophages can be differentiated from hematopoietic stem cells by treating Macrophage Colony-stimulating factor (M-CSF) in the process. In the step, macrophage colony-stimulating factor (M-CSF) is treated to differentiate into macrophages after maximally maintaining and culturing cells induced to differentiate into hematopoietic stem cells. In said step, macrophage colony-stimulating factor (M-CSF) is also treated on the cells differentiated from granulocyte-macrophage progenitor cells in the hematopoietic stem cells.

One embodiment of the invention includes the step of treating the macrophage colony stimulating factor and interleukin-3 simultaneously or sequentially. When interleukin-3 is treated first, the differentiation rate of bone marrow hematopoietic stem cells can be increased, and when macrophage colony stimulating factor (M-CSF) is treated later, since bone marrow hematopoietic stem cells are mostly differentiated into macrophages, macrophages can be produced with high purity, and the yield is higher than that of the known differentiation method.

Also, the method of treating sequentially has a higher yield than the method of treating macrophage colony stimulating factor and interleukin-3 simultaneously.

In this step, macrophage colony-stimulating factor (M-CSF) can be treated at an initial concentration of 100ng/ml and after a period of time, its concentration can be reduced to 20 ng/ml.

In the case of differentiating macrophages from pluripotent stem cells according to the method for inducing differentiation of the present invention, the induced hematopoietic stem cells have the property of being granulocyte-macrophage progenitor cells, and after obtaining the maximum granulocyte-macrophage progenitor cells before the treatment with macrophage colony stimulating factor, they are differentiated into macrophages at a time, so that the yield of macrophages can be increased.

The present invention relates to a method of inducing differentiation of hematopoietic stem cells comprising: step 1), culturing pluripotent stem cells in a medium for inducing differentiation of hematopoietic stem cells, the medium comprising bone morphogenetic protein 4; step 2), culturing the pluripotent stem cells by treating vascular endothelial growth factors and stem cell factors; and step 3) treating said pluripotent stem cells with thrombopoietin, interleukin-6, interleukin-3, and FMS-like tyrosine kinase 3.

In step 1) of the method for inducing differentiation of the present invention, since one or more of activin a, basic fibroblast growth factor, and transforming growth factor b are not additionally included, the amount of cytokines used can be reduced.

In the step 1), it is preferable that the bone morphogenetic protein 4 is contained at a concentration of 20 to 100ng/ml, and after the bone morphogenetic protein 4 is treated at a low concentration in an initial stage, it is preferable that the bone morphogenetic protein is treated at a high concentration again.

The medium for inducing differentiation of hematopoietic stem cells is preferably albumin, a polyvinyl alcohol essential lipid.

The present invention relates to a method of inducing macrophage differentiation, comprising: step 1), culturing pluripotent stem cells in a medium for inducing differentiation of hematopoietic stem cells, the medium comprising bone morphogenetic protein 4; step 2), culturing the pluripotent stem cells by treating vascular endothelial growth factors and stem cell factors; step 3) inducing hematopoietic stem cell differentiation by treating said pluripotent stem cells with thrombopoietin, interleukin-6, interleukin-3, and FMS-like tyrosine kinase 3; and step 4) adding the differentiated hematopoietic stem cells to a macrophage differentiation-inducing medium containing a macrophage colony-stimulating factor for culturing.

In the 4), preferably, the cell density is maintained at 1X 10 when the macrophage cell is cultured⁵Cells/cm²The above.

The present invention relates to hematopoietic stem cells differentiated from pluripotent stem cells by the method for inducing hematopoietic stem cell differentiation.

The present invention relates to a method for inducing differentiated macrophages from pluripotent stem cells by the method for inducing hematopoietic stem cell differentiation.

The present invention relates to a composition for inducing differentiation of hematopoietic stem cells derived from pluripotent stem cells, comprising at least one member selected from the group consisting of bone morphogenetic protein 4, vascular endothelial growth factor, stem cell factor, thrombopoietin, interleukin-6, interleukin-3, CDDO methyl ester, and FMS-like tyrosine kinase 3.

The present invention also relates to a composition for inducing differentiation of pluripotent stem cell-derived macrophages, comprising at least one member selected from the group consisting of bone morphogenetic protein 4, vascular endothelial growth factor, stem cell factor, thrombopoietin, interleukin-6, interleukin-3, FMS-like tyrosine kinase 3, and macrophage colony stimulating factor.

In the present invention, the term "pluripotent stem cell" refers to a stem cell having differentiation pluripotency, and is a stem cell that can differentiate into endodermal, mesodermal, ectodermal cells or tissues. Although the source of the cells is not particularly limited, human embryonic stem cells and retrodifferentiated stem cells are included.

In the present invention, the term "mesodermal cell" refers to a cell that can be induced by a signaling molecule element for regulating the differentiation of stem cells, particularly, differentiated through the bone morphogenetic protein 4 signaling pathway. The mesodermal cells of the present invention may include mesodermal cells whose differentiation is regulated by bone morphogenic protein 4, and may include all cells that differentiate into hematopoietic mesoderm via mesodermal cells.

In the present invention, the term "hematopoietic stem cell" is also referred to as "hematopoietic progenitor cell" as a hematopoietic cell that can potentially differentiate into a main component of blood. Hematopoietic cells can be differentiated into cells generated from fetal liver (total liver) during a developmental step, cells generated from yolk sac (yolk sac), and cells generated from bone marrow after birth, and differentiated into lymphoid (lymphoid) and myeloid (myeloid) type cells. The hematopoietic stem cells of the present invention can be differentiated into macrophages.

In the present invention, the term "macrophage" is responsible for innate immunity, can exist in the blood as a monocyte and can differentiate into dendritic cells or macrophages. Macrophages exert a bacterial or viral removing action, which is denoted as phagocytosis (phagocytosis). Macrophages differentiated by the induced differentiation process of the present invention can be used in research models of viral or bacterial infection.

In the present invention, the term "differentiation" refers to a process in which non-specialized cells develop into specific cells, and particularly includes a process in which stem cells develop into specific cells. In the present invention, embryonic stem cells and retrodifferentiated stem cells that can be finally differentiated into macrophages by mesodermal cells and hematopoietic stem cells are used as cells having a differentiation ability.

In the present invention, the term "signal substance" is a concept including a signal protein, cytokine, catalyst, etc. involved in the differentiation of pluripotent stem cells. In particular, the invention comprises bone morphogenic proteins, macrophage colony stimulating factor, vascular endothelial growth factor, stem cell factor, thrombopoietin, interleukin-6, interleukin-3, and FMS-like tyrosine kinase 3.

In the invention, CDDO methyl ester is used as an Nrf2 activating material and refers to a compound of 2-cyano-3,12-dioxooleana-1,9(11) -diene-28-methyl oleate (2-cyano-3, 12-dioxoleana-1, 9(11) -diene-28-oic acid methyl ester).

The present invention will be described in more detail below with reference to examples. These examples are merely intended to more specifically illustrate the present invention, and the scope of the present invention is not limited to these examples.